The development of “Noltec”, the nation’s 14th new indigenous drug, dates back to 1987 which is before the 88 Olympic Games were held in Seoul, and is the result of the efforts over more than 2 decades to create the growth engine and cope with the introduction of the substance patent in 1987 for the first time nationwide. Noltec represents the culmination of constant and intensive R&D as part of major state-funded projects such as the leading technology development project(G7 project) driven forward by the Ministry of Science and Technology in 1992 and new drug development project led by the Ministry of Health and Welfare in 1998, and has come into limelight for its efficacy even before the launch as the nation’s 14th new indigenous drug. As a result, Noltec provides the strongest inhibition of gastric acid secretion among the PPI agents currently available in the market and has proven excellent efficacy providing the lasting effect with a single dose per day. Noltec added the indications of reflux esophagitis, and has achieved drastic sales growth and sharp increase of the share in the market for esophageal ulcer drugs. As the reflux esophagitis incidents have increased with a recurrence rate of 80%, the market for reflux esophagitis drugs – which comprise more than 80% of all anti-ulcer drugs – has seen an increasing need for constant maintenance therapy. Meanwhile, South East Asia and Korea has seen a shift in focus from gastric ulcer/duodenal ulcer treatment drugs to reflux esophagitis drugs. This has led to higher marketability and value of “Noltec”, creating an opportunity for this new drug to gain ground in global market beyond South East Asia.

Nolte makes foray into peptic ulcer market worth KRW 600 billion

Noltec has made foray into peptic ulcer market worth approximately KRW 600 billion and accounting for 80% of PPI agents on the back of the addition of the indication for reflux esophagitis, moving beyond the market valued at KRW 40 billion. As a result, Noltec, which has the most excellent efficacy and longest lasting effect among the PPI agents, is expected to rake in huge amounts in sales comparable to those of the existing major products simply by adding the indication for reflux esophagitis.